M.S. Saag1, *, M. Holodniy2, D.R. Kuritzkes3, W.A. O'Brien4, R. Coombs5, M.E. Poscher6, D.M. Jacobsen7, G.M. Shaw1, D.D. Richman8
& P.A. Volberding6
1University of Alabama at Birmingham
2Stanford University and the Palo Alto Veterans Affairs Health Care System
3University of Colorado Health Sciences Center
4University of California Los Angeles School of Medicine and West Los Angeles Veterans Affairs Medical Center
5University of Washington
6University of California San Francisco School of Medicine
7International AIDS Society−USA
8University of California San Diego and San Diego Veterans Affairs Medical Center
*University of Alabama at Birmingham, 908 20th Street South Birmingham, Alabama 35294-2050, USA
Plasma HIV RNA determinations are an important prognostic marker of disease progression and, when used appropriately, provide a valuable tool for the management of individual patients. But what constitutes appropriate use?
REFERENCES
Wei, X. et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature373, 117 (1995). | Article | PubMed | ISI | ChemPort |
Ho, D.D. et al. Rapid turnover of plasma virions and CD4+ lymphocytes in HIV-1 infection. Nature373, 123−126 (1995). | Article | PubMed | ISI | ChemPort |
Ho, D.D., Moudgil, T. & Alam, M. Qunatitation of human immunodeficiency virus type 1 in the blood of infected persons. N. Engl. J. Med.321, 1621−1625 (1989). | PubMed | ISI | ChemPort |
Coombs, R.W. et al. Plasma viremia in human immunodeficiency virus infection. N. Engl. J. Med.321, 1626−1631 (1989). | PubMed | ISI | ChemPort |
Piatak, M., Jr et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science259, 1749−1754 (1993). | PubMed | ISI | ChemPort |
Pachl, C. et al. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. J. Acquir. Immune Defic. Syndr. Hum. Retrovir.8, 446−454 (1995). | ISI | ChemPort |
Mulder, J. et al. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: Application to acute retroviral infection. J. Clin. Microbiol.32, 292−300 (1994). | PubMed | ISI | ChemPort |
Kievits, T. et al. NASBA isothermal enzymatic in vitro nucleic acid amplification optimized for the diagnosis of HIV-1 infection. J. Virol. Methods35, 273−286 (1991). | Article | PubMed | ISI | ChemPort |
Cao, Y. et al. Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. AIDS Res. Hum. Retrovir.11, 353−361 (1995). | PubMed | ISI | ChemPort |
Lin, H.J. et al. Multicenter evaluation of quantification methods for plasma human immunodeficiency virus type 1 RNA. J. Infect. Dis.170, 553−562 (1994). | PubMed | ISI | ChemPort |
Brambilla, D. et al. Variation in estimates of HIV-1 plasma RNA concentration among laboratories and assay kits. 3rd Conference on Retroviruses and Opportunistic Infections, Jan. 28−Feb. 1, 1996, 155, abst. 550 (Washington, DC).
Holodniy, M., Mole, L., Winters, M. & Merigan, T.C. Diurnal and short-term stability of HIV virus load as measured by gene amplification. J. Acquir. Immune Defic. Syndr.7, 363−368 (1994). | PubMed | ISI | ChemPort |
Clark, S.J. et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N. Engl. J. Med.324, 954 (1991). | PubMed | ISI | ChemPort |
Holodniy, M. et al. Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction. J. Infect. Dis.163, 862−866 (1991). | PubMed | ISI | ChemPort |
Stein, D.S., Korvick, J.A. & Vermund, S.H. CD4+ lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review. J. Infect. Dis.165, 352−363 (1992). | PubMed | ISI | ChemPort |
Raboud, R.M. et al. Quantification of the variation due to laboratory and physiologic sources in CD4 lymphocyte counts of clinically stable HIV-infected individuals. J. Acquir. Immune Defic. Syndr. Hum. Retrovir.10 (suppl. 2), S67−S73 (1995). | ISI |
Hoover, D.R. et al. Effect of CD4+ cell count measurement variability on staging HIV-1 infection. J. AIDS5, 794−802 (1992). | ChemPort |
O'Brien, W.A. et al. Changes in plasma HIV-1 RNA and CD4+ Lymphocyte counts and the risk of progression to AIDS. N. Engl. J. Med.334, 425−431 (1996). | Article |
Coombs, R.W. et al. Association of plasma human immunodeficiency virus type-1 RNA level with risk of clinical progression in patients with advanced infection. J. Infect. Dis. (in the press).
Welles, S.L. et al. Prognostic value of plasma HIV-1 RNA levels in patients with advanced HIV-1 disease and with little or no zidovudine therapy. J. Infect. Dis. (in the press).
Mellors, J.W. et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann. Intern. Med.122, 573−579 (1995). | PubMed | ISI | ChemPort |
Mellors, J.W. et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science (in the press).
Kappes, J.C. et al. Assessment of antiretroviral therapy by plasma viral load testing: standard and ICD HIV-1 p24 antigen and viral RNA j(QC-PCR) assays compared. J. Acquir. Immune Defic. Syndr. Hum. Retrovir.10, 139−149 (1995). | ISI | ChemPort |
Hammer, S.M., Katzenstein, D.A., Hughes, M.D., Hirsch, M.S., Merigan, T.C. Virologic markers and outcome in ACTG 175. 3rd Conference on Retroviruses and Opportunistic Infections, Jan. 28−Feb. 1, 1996, 175, abst. S24 (Washington, DC).
Eron, J. et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4 cells per cubic millimeter. N. Engl. J. Med.333, 1662−1669 (1995). | Article | PubMed | ISI | ChemPort |
Danner, S.A. et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N. Engl. J. Med.333, 1528−1533 (1995). | Article | PubMed | ISI | ChemPort |
Markowitz, M. et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N. Engl. J. Med.333, 1534−1539 (1995). | Article | PubMed | ISI | ChemPort |
Heath-Chiozzi, M. et al. Anti-HIV activity and lymphocyte surrogate marker response dynamics to ritonavir therapy in advanced HIV immunodeficiency. 3rd Conference on Retroviruses and Opportunistic Infections, Jan. 28−Feb. 1, 1996, 162, abst. LB6b (Washington, DC).
Havlir, D., McLaughlin, M.M. & Richman, D.D. A pilot study to evaluate the development of resistance to nevirapine in asymptomatic human asymptomatic human immunodeficiency virus-infected patients with CD4+ cell counts of >500/mm3: AIDS Clinical Trials Group Protocol 208. J. Infect. Dis.172, 1379−1383 (1995). | PubMed | ISI | ChemPort |
Holodniy, M. et al. Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy. J. Virol.69, 3510−3516 (1995). | PubMed | ISI | ChemPort |
Staprans, S.I. et al. Activation of virus replication after vaccination of HIV-1 infected individuals. J. Exp. Med.182, 1727−1737 (1995). | PubMed | ISI | ChemPort |
O'Brien, W.A. et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood86, 1082−1089 (1995). | PubMed | ChemPort |
